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How to Manage the Obese Patient With Cancer
Andrew G. Renehan, Michelle Harvie, Ramsey I. Cutress, Michael Leitzmann, Tobias Pischon, Sacha Howell, and
Anthony Howell
A B S T R A C T
Purpose
Obesity (body mass index [BMI]$ 30 kg/m2) is common among patients with cancer. We reviewed
management issues in the obese patient with cancer, focusing on how obesity influences treatment
selection (including chemotherapy dosing), affects chemotherapy toxicity and surgical complica-
tions, and might be a treatment effect modifier.
Methods
The majority of evidence is drawn from observational studies and secondary analyses of trial data,
typically analyzed in N3 3 BMI categories (normal weight, overweight, and obese)matrix structures.
We propose a methodological framework for interpretation focusing on sample size and compo-
sition, nonlinearity, and unmeasured confounding.
Results
There is a common perception that obesity is associated with increased treatment-related toxicity.
Accordingly, cytotoxic chemotherapy dose reduction is common in patients with elevated BMI.
Contrary to this, there is some evidence that full dosing in obese patients does not result in increased
toxicity. However, these data are from a limited number of regimens, and fail to fully capture
cytotoxic drug pharmacodynamics and pharmacokinetic variability in obese patients. Among pa-
tients undergoing surgery, there is evidence that elevated BMI is associated with increased
perioperative mortality and increased rates of infectious complications. A novel finding is that these
relationships hold after surgery for malignancy, but not for benign indications. There are biologic
plausibilities that obesity might be an effect modifier of treatment, but supporting evidence from
clinical studies is inconsistent.
Conclusion
In line with the ASCO 2012 guidelines, chemotherapy dosing is probably best performed using
actual body weight in obese patients. However, specific regimens known to be associated with
increased toxicity in this group should be used with caution. There is no guidance on dose for obese
patients treated with biologic agents. Currently, there are no specific recommendations for the
surgical management of the obese patient with cancer.
J Clin Oncol 34:4284-4294. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Excess body weight, commonly expressed as
elevated body mass index (BMI; overweight and
obesity), is an established risk factor for several
incident adult cancers.1 The International Agency
for Research on Cancer2 lists 13 obesity-related
cancers, which include esophageal adenocarci-
noma; cancers of the gastric cardia, colorectum,
liver, gallbladder, pancreas, postmenopausal breast,
endometrium, ovary, kidney (renal cell), and
thyroid; meningioma; and multiple myeloma.
Thus, for many cancer types, the proportions
of patients with obesity (BMI $ 30 kg/m2) are
high. For example, the ranges (11% to near 50%)
of the proportions of obese patients by some cancer
types are endometrial, 39% to 47%; renal cell
carcinoma, 42%; rectal, 18% to 37%; esophageal
adenocarcinoma, 35%; GI and colon, 18% to
26%; ovarian, 12% to 15%; breast, 11% to 27%;
and metastatic colorectal cancer, 12% (Data
Supplement).
We review management issues in the obese
patient with cancer, focusing on how obesity
influences treatment selection (including che-
motherapy dosing), affects chemotherapy toxicity
and surgical complications, andmight be a treatment
effect modifier. We also include a number of specific
miscellaneous aspects that are relevant to the
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treatment of the obese patient with cancer, but are not covered
elsewhere in this Special Issue.
METHODS
The majority of evidence is drawn from observational studies and sec-
ondary analyses of trial data, typically analyzed in N 3 3 BMI categories
(normal weight, overweight, and obese) matrix structures.We first propose
a methodological framework to interpret this structure. Because of the
wide scope of this review, a formal literature search of observational studies
was deemed impracticable.
Sample Size and Composition
Case studies in the Data Supplement illustrate the following: small
study size can result in both type 1 and type 2 statistical errors in re-
lationships of proportions of interest (eg, complications) and BMI cate-
gories (for this reason, in this review, we have cited studies with greater
than 1,000 participants, wherever possible); tabulations with greater than
two rows of interest (eg, three histologic grades) can be difficult to in-
terpret; and for the same effect size between obese versus normal-weight
individuals, with an increasing size of the proportions of obese within
a cohort, there is an increased likelihood of statistical significance.
Obesity and Outcomes As Nonlinear Relationships
Obesity is associated with increased risk of incident cancers3 and may
also be associated with poorer prognosis, especially in breast cancer (and
dealt with elsewhere in this Special Issue4). These relationships might be
nonlinear. Similarly, there might be several types of nonlinear relationships
between BMI and the event of interest closer to the treatment window,
such as perioperative mortality. These are illustrated in Fig 1 and might
include U-shaped curve; inverse J-shaped curve, as observed between BMI
and 30-day mortality byMullen et al5 in their analysis of 2,258 patients who
underwent major intraabdominal cancer surgery; a bimodal curve, as
observed between BMI and in-hospital mortality after coronary artery
bypass graft (CABG) surgery6; and a fourth relationship known as the
obesity paradox.7 The latter is the observation of an unexpected risk
reduction in an outcome of interest (usually mortality, but could be
peritreatment mortality) among individuals with elevated BMI ($ 25 kg/m2),
in whom an increased risk is anticipated, compared with those of normal
weight (18.5 to 25 kg/m2).
Once the many types of nonlinear relationships are recognized, one
can appreciate that simple BMI categorizations into normal weight,
overweight, and obese might be misleading. For example, in scenario (C)
in Figure 1, a patient with a BMI = 30 kg/m2 might have a similarly low
probability of a complication as a normal-weight patient, but this might
hide the possibility that this complication is substantially increased in
higher obese states.
Unmeasured Confounding
For cancer incidence (cohort) studies, there is usually a large array
of variables (potential confounders), including smoking status, alcohol
consumption, level of education, and socioeconomic status. Taking ac-
count of these potential confounders and effect modifiers is important. For
example, stratification by smoking status is relevant in the interpretation of
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Fig 1. Schematic diagrams of various nonlinear
patterns of relationships between body mass
index (BMI) and odds ratio of outcome of interest
(for example, perioperative mortality). (A) U-
shaped; (B) inverse J-shaped; (C) bimodal curve;
and (D) obesity paradox (the latter modified from
Lennon et al7).
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studies of obesity exposure and incident cancer risk,8 because smokers have
lower mean BMI values compared with those of never smokers. Un-
fortunately, data on smoking status are infrequently collected in oncology
trials (ie, an unmeasured confounder), yet smoking might have major
influence on early outcomes such as postoperative complications, peri-
treatment mortality, and toxicity.
RESULTS
Treatment Selection
Selection for specific treatment modalities. Studies have
addressed the influence of obesity on the decision to offer certain
types of cancer treatments, in specific settings. For example,
a review of the National Comprehensive Cancer Network centers’
breast cancer data (N = 9,527; stages I, II, and III; 1997 to 2007)
showed that BMI had no effect on the decision to offer adjuvant
chemotherapy.9 Similarly, in rectal cancer, there appears to be no
difference in the decision to perform an abdomino-perineal re-
section versus an anterior resection (a colostomy avoiding oper-
ation) between obese versus nonobese patients.10
In contrast, obesity negatively influences the decision for im-
mediate breast reconstruction after mastectomy.11 In 2007, van de
Poll-Franse et al,12 using broad modalities of treatments (surgery,
radiotherapy, and chemotherapy) recorded in the Eindhoven Cancer
Registry, concluded that patients with diabetes (an obesity-related
condition) and cancer of the esophagus, colon, breast, or ovary were
treated less aggressively (received fewer treatment modalities) com-
pared with those without diabetes. However, this simplistic classifi-
cation of aggressiveness of treatment is probably not applicable today
because present-day management is both multimodal and across
multiple phases.
Chemotherapy dosing. In contrast, once a decision is made to
offer chemotherapy, there is a large volume of data showing that
oncologists frequently reduce doses when prescribing in obese
patients because of concerns about toxicity. This philosophy has
been challenged for a long time.13 Table 1 summarizes a number of
studies evaluating chemotherapy dose reductions according to BMI
categories in breast,14,15 colorectal,16,17 and ovarian18,19 cancers.
This tabulation illustrates that, even within trials, obesity is as-
sociated frequently with reduced chemotherapy intensity (ie, re-
duced frequency and/or failure to complete the prescribed regimen).
For example, in an ovarian cancer trial, 66% of obese patients
received suboptimal chemotherapy intensity compared with
30% for those of normal weight.18
What are the consequences of the fact that a high proportion
of obese patients with cancer are treated by reduced doses? Among
trials where participants received reduced doses of adjuvant che-
motherapy, and where the adjuvant chemotherapy is known to
improve survival, there is evidence in several cancer types (breast,20-22
colorectal,16,23 lung,24 and lymphoma21) that survival advantages are
lost and outcomes are similar to those of the untreated or control
cohorts. Importantly, the implication of this is that the observed
adverse prognosis associated with obesity in many cancer types
(discussed in other reviews in the Special Issue4) may reflect con-
founding as a result of suboptimal chemotherapy dosing and reduced
therapeutic effect relative to normal-weight patients with cancer,25
rather than obesity per se.
Impact of Obesity on Treatment Complications
Chemotherapy toxicity. Hourdequin et al26 recently reviewed
and meta-analyzed data that evaluated toxic effects of chemo-
therapy dosing using actual body weight (ABW) in obese versus
normal-weight patients with cancer. Against conventional ex-
pectations, the summary risk estimates initially suggested that
obese patients experience less hematologic toxicity when dosed
using ABW, and that among patients in trials where full che-
motherapy doses were received, any grade 3/4 toxicities were
fewer in obese versus normal-weight participants (summary
odds ratio favoring obese patients, 0.75; 95% CI, 0.65 to 0.87).
However, such conclusions rely heavily on colorectal trials in-
vestigating fluorouracil-based regimens, and other trials in breast
cancer and lymphoma showed no effect.26 More recent data from
3,023 patients with breast cancer, published after this meta-
analysis, demonstrate an increase in severe toxicity in ABW-
dosed obese patients given dose-intense anthracycline- and
taxane-containing regimens.27
A further dimension is that BMI is a crude approximation
of body adiposity and fails to fully capture cytotoxic drug phar-
macodynamic and pharmacokinetic variability in obese patients.
In the largest analysis to date (N = 1,206) of the effect of obesity on
the pharmacokinetics of cytotoxic drugs, Sparreboom et al28
showed drug-specific interactions between BMI and pharmaco-
kinetic clearance, and sex-specific interactions for drugs such as
doxorubicin.
There is a paucity of toxicity data on new biologic agents in
obese patients with cancer. One recent review demonstrated in-
creased cardiac toxicity associated with Herceptin administration
in obese patients.29 Traditionally, Herceptin has been dosed per
kilogram when an intravenous route is used. However, in many
countries (but not in the United States), the administration has
been changed to subcutaneous delivery as a single standard 600-mg
dose. Detailed pharmacokinetic data show that this alteration
results in reduced exposure in obese patients, but the impact on
toxicity and survival has yet to be assessed.30
In conclusion, data in large adjuvant trial databases should be
analyzed to increase our understanding. The observation that fat
distribution may have a greater effect on cytotoxic clearance than
obesity per se, as well as the complexities of the influence of ge-
netics on pharmacokinetics, suggests that detailed prospective
studies of tailoring chemotherapy doses to the individual are
required.31,32
Surgical complications and perioperative mortality. There is
a common perception that obesity is associated with increased
postsurgical morbidity and mortality, but there are caveats to this
dictum. Table 2 lists studies evaluating relationships among ele-
vated BMI, major complications, and perioperative mortality after
nonbariatric, nonvascular general surgery. Many studies were
cancer only5,33-36 whereas others included benign and malignant
indications,37-39 which were included to demonstrate that there
might be an effect modification by indication. The summary from
this tabulation is that elevated BMI is associated with increased
perioperative mortality and increased rates of infectious com-
plications, but that there are inconsistent associations between
elevated BMI categories and composite (eg, Clavien-Dindo
III/IV) or total postsurgical complications. Relationships might
be site specific. Thus, for example, for breast reconstruction after
4286 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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mastectomy, obesity is likely to be an adverse factor for wound
and infectious complications.34,40
What is interesting is the emerging evidence that the in-
dication for surgery might be an effect modifier. This is clearly
illustrated in the recently published STARSurgUK study,37 where
there were no effects of increased BMI on complications after
surgery for benign disease (indeed, there was some evidence of an
inverse relationship), but clear (positive) relationships between
BMI and postsurgical complications in cases where the surgical
indication was malignant disease. This is an important new ob-
servation that may explain previous inconsistencies in the litera-
ture. It could also reflect that surgeons are highly selective or even
avoid operating on obese individuals for benign conditions (and
even advocate weight loss before some surgeries for benign
indications).
There are other observations worth mentioning. For patients
undergoing abdominal laparoscopic surgery for intraabdominal
malignancy, there is a recognized increased risk for open conversion
with increasing BMI. For the Cleveland Clinic Colorectal Laparo-
scopic Conversion Score,41 BMI is a key predictor; eg, for a teamwith
75 to 100–patient experience, the predicted conversion rate increases
from 2.4% in subjects with a BMI , 22 kg/m2 to 7.4% in subjects
with a BMI . 28.5 kg/m2 undergoing right hemicolectomy surgery.
Obesity might have an impact on intermediate-term complications
after abdominal cancer surgery, such as incisional and parastomal
hernia development. The US Muscle and Adiposity Research Con-
sortium42 reported a rate of 21% incisional hernia formation
(median time, 12 months), and that visceral obesity (quantified on
routine computed tomography imaging) was a better predictor
than BMI for this occurrence.
Obesity As a Treatment Effect Modifier
It is increasingly recognized that the response to specific
cancer therapies differs significantly as a result of different tumor
and patient characteristics. These characteristics are termed
treatment effect modifiers or treatment predictive biomarkers, and
are distinct from prognostic biomarkers.43 Obesity is a potential
predictive biomarker.
In the setting of aromatase inhibitors (AIs) as hormonal
therapy for breast cancer, because obesity is associated with in-
creased peripheral aromatase activity (the target for AIs), it is
hypothesized that these agents might be less effective in overweight
and obese women (addressed by Goodwin44 and within sections of
this Special Issue45). Secondary analyses of four randomized trials
found inconsistent results44 and concluded that the findings did
not support the use of BMI as a treatment predictive biomarker of
AIs (v tamoxifen) in the adjuvant setting in women with post-
menopausal breast cancer.
There is some evidence that antiangiogenic agents, such as
bevacizumab (dosed per kilogram of weight rather than body
surface area), might be less effective in obese patients. Excess
adiposity is associated with increased circulating levels of
vascular endothelial growth factor,46 a key regulator of tumor
angiogenesis and the main target for bevacizumab antibody
therapy; hence, there is a biologic plausibility that obesity
might be a potential predictive biomarker in this setting.
This has been tested in the settings of metastatic colorectal
cancer47,48; metastatic renal cell carcinoma49,50; and advanced
ovarian cancer51 (listed in Table 3).
Several of these studies were retrospective, had small sample
sizes, lacked controls of conventional treatment arms, and were
underpowered to perform tests for interaction; not unexpectedly,
the findings are inconsistent. Some studies support the notion that
antiangiogenic agents are less effective in obese patients with
metastatic colorectal47 and advanced ovarian cancer51; the opposite
is noted in metastatic renal cancer49,50; and no difference was seen
in the largest analysis, which was a secondary analysis of two trials
in metastatic colorectal cancer.48 We conclude that currently,
obesity is not a treatment predictive biomarker for antiangiogenic
therapies in these cancers.
Miscellaneous Matters
There are a number of issues that require specific discussion
regarding the obese patient with cancer, which are not covered
elsewhere in this Special Issue.
Weight gain during chemotherapy. All discussion on this
matter relates to women with breast cancer. Historically, women
who received first-generation nonanthracycline-containing che-
motherapy regimens received concomitant corticosteroid therapy,
and this contributed substantially to weight gain. Weight gain
continues to be seen inwomen on contemporary regimens of 4.5 to
6 months of anthracycline and taxane chemotherapy, but again,
concomitant administration of corticosteroid may contribute. Ex-
amples of prospective studies from the United States,52 Europe,53
and Asia54 report that 30% to 50% of women gain . 5% of body
weight, with a mean weight change of 2 to 3 kg in the first year after
diagnosis, although this is not reported in all cohorts.55-58
Greatest weight gain is observed among women who are pre-
menopausal, have a healthy weight at diagnosis,59 stop smoking after
diagnosis,60 or experience a chemotherapy-induced menopause.58,61
Weight gains may be greater with cyclophosphamide, methotrexate,
and fluorouracil compared with anthracycline (2.9 kg [5%] v 0.9 kg
[1%]),62 but this is not a consistent finding.52,61,63 Weight is gained
both during and after the chemotherapy period,58,64 and has
been shown to persist when measured at 3 years52 and 6 years65
after diagnosis.
What are the consequences of chemotherapy-related weight
gain? Playdon et al66 addressed this question in a meta-analysis of
23,832 cancer cases from seven cohorts and two chemotherapy
trials. They reported that compared with women who maintained
stable weight, those who experienced $ 10% weight gains after
diagnosis had increased overall mortality (hazard ratio [HR], 1.23;
95% CI, 1.09 to 1.39), and to a lesser extent increased breast cancer
mortality (HR, 1.17; 95% CI, 1.00 to 1.38). But there was no as-
sociation between weight gain and recurrence. However, the meta-
analysis highlighted considerable between-study heterogeneity and
on close scrutiny, most of the increased risk was within the first
years after cancer diagnosis and driven by two studies,67,68 raising
concerns of reverse causality.
A recently reported pooled project analysis, from the WHEL,
LACE, and NHS cohorts,69 addressed the question of specificity of
associations among 6,596 women with estrogen receptor–positive
tumors, and in contrast to the Playdon review,66 linked $ 10%
weight gain with increased risk of late recurrence, defined
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as . 5 years after diagnosis (HR, 1.24; 95% CI, 1.00 to 1.53).
However, this significant finding was isolated; no associations
were seen for any weight gain and late all-cause mortality. Several
randomized trials of lifestyle and weight control interventions in
breast cancer survivors, with survival end points, are currently
ongoing and covered elsewhere in this special issue.70 However,
for the most part, recruitment is after treatment and these
studies are unlikely to directly address the chemotherapy-related
weight gain conundrum.
Excess body weight, noncancer and cardiovascular
mortalities. Noncancer deaths may be an issue both during and
years after cancer treatment. The ASCO position statement4,71 on
obesity and cancer recognized that excess body weight might
contribute to increased mortality through noncancer deaths, and
that of these, approximately half are as a result of cardiovascular
disease. However, only a small number of studies have directly
addressed this relationship (Data Supplement). For breast cancer,
the systematic review and meta-analysis from Chan et al72 iden-
tified five studies that evaluated the association between BMI
(determined , 12 months after diagnosis) and noncancer
mortality. Compared with normal BMI, the HRs were increased
for obesity (but not overweight), but these were not statistically
significant. Similarly, the HRs of cardiovascular deaths were
increased among obese women compared with those of normal
weight (based on pooled data in the Chan meta-analysis72 from
two studies, where BMI was measured before cancer diagnosis),
but these were not statistically significant. In the After Breast
Cancer Pooling Project,73 which was not included in the Chan
meta-analysis,72 women who were obese II and III before breast
cancer diagnosis (compared with normal weight) were at in-
creased risk of non-breast cancer deaths.
For colorectal cancer, Campbell et al74 demonstrated a sig-
nificantly increased risk of cardiovascular death with increasing
prediagnosis (mean, 7 years) BMI (per 5 kg/m2: HR, 1.28; 95% CI,
1.04 to 1.58), but not postdiagnosis (mean, 1.5 years) BMI (per
5 kg/m2: HR, 1.06; 95% CI, 0.84 to 1.33). For endometrial cancer,
Ward et al75 used the SEER registries, and although they were
unable to establish a link with BMI, approximately half of women
with endometrial cancer are estimated to be obese.76 They con-
cluded that “cardiovascular disease is the leading cause of death
among endometrial cancer patients and survivors.”
Excess body weight and quality of life. There is a common
perception that obesity among cancer survivors has negative
consequences on quality of life (QoL).59 The prevailing argument is
that trials among cancer survivors generally demonstrate that
lifestyle interventions that lead to weight reduction are associated
with increased physical activity, improved QoL, and less fatigue.71
However, these trials are short term and it remains unclear whether
a long-term state of excess body weight per se is associated with
reduced QoL in cancer survivors. A number of reviews have
addressed this question: one study in multiple cancer types77; two
studies in breast cancer survivors78,79; one meta-analysis of 10
studies in colorectal cancer80; one meta-analysis of five studies in
prostate cancer81; one meta-analysis of four studies in endome-
trial cancer82; and one study in ovarian cancer survivors83 (Data
Supplement).
QoL measures were determined using a variety of different
assessment tools and at varying times during survivorship, making
direct comparisons difficult. Overall, there were consistent findings
that obesity is associated with reduced physical function and reduced
vitality, but there was no consistent association for mental health or
cognitive function. In a recent review, Smits et al82 recognized that
sociodemographic factors and the presence of comorbidities are key
determinants of QoL, but these are infrequently available in adjusted
models in the cancer survivorship setting. Furthermore, and im-
portantly, almost no study among cancer survivors included ap-
propriately matched noncancer control subjects. One exception is
the recently published data from the Long-Term Quality of Life
Study in breast cancer survivors,78 which reported decreased
physical function on SF-36 surveys among obese survivors, but this
was also observed among obese individuals without cancer.
PRACTICE RECOMMENDATIONS
ASCO Clinical Practice Guideline
The question of chemotherapy dosing in the obese patient was
the subject of an ASCO 2012 clinical practice guideline.84 The
Panel84 made six clear clinical recommendations regarding these
questions, summarized in Table 4. The recommendations high-
lighted that ABW should be used for chemotherapy dosing, re-
gardless of obesity status. Our updated review broadly agrees with
these guidelines. However, specific regimens known to be asso-
ciated with increased toxicity in this group should be used with
caution, and this should be taken into account in initial dose
selection.
As yet, there is no equivalent guidance for biologic agents (for
example, Herceptin and bevacizumab). Currently, there are no
specific recommendations for the surgical management of the
obese patients with cancer.
Future Research
This review has highlighted that BMI is a crude measure of
body adiposity and fails to capture cytotoxic drug pharmacodynamic
Table 4. Summaries of Key Recommendations From the ASCO Clinical
Practice Guidelines on Appropriate Chemotherapy Dosing for Obese Adult
Patients With Cancer84
Question Summary Recommendations
1 ABW be used when selecting cytotoxic chemotherapy doses
regardless of obesity status
2 Full weight–based chemotherapy doses (IV and oral) be used in
the treatment of the obese patient with cancer, particularly
when the goal of treatment is cure
3 Clinicians should follow the same guidelines for dose reduction,
regardless of obesity status, for all patients, depending on the
type and severity of toxicity, any comorbid conditions, and
whether the treatment intention is cure or palliation
4 Consideration of fixed dosing only with select cytotoxic agents
(eg, carboplatin, bleomycin, vincristine)
5 BSA be calculated using any of the standard formulae
6 To the sixth question, the Panel recommended “further
research into the role of pharmacokinetic and
pharmacogenetic information for guiding the dosing of IV and
oral chemotherapeutic agents for adult patients with cancer
who are obese.”
Abbreviations: ABW, actual body weight; BSA, body surface area; IV,
intravenously.
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and pharmacokinetic variability in obese patients. There is
a need to initiate studies to better assess body composition (for
example, computed tomography– or magnetic resonance–
derived anthropometric measures such as visceral and sub-
cutaneous adipose tissue85; and dual-energy x-ray absorpti-
ometry86) and early outcomes (such as complications and
toxicity). Although BMI is the most common measure used to
characterize body composition, it cannot distinguish lean mass
from fat mass, determine sarcopenic obesity, or characterize body fat
distribution. This relationship may differ for individuals with or
without cancer, a strategy detailed elsewhere,86 and is important
to pursue to better define the management of the increasing pro-
portion of obese patients with cancer.
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